{"id":"NCT01495702","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","officialTitle":"A Phase 3b Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-11","completion":"2014-12","firstPosted":"2011-12-20","resultsPosted":"2015-01-26","lastUpdate":"2016-01-07"},"enrollment":439,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Immunodeficiency Syndrome","HIV Infections"],"interventions":[{"type":"DRUG","name":"NNRTI","otherNames":[]},{"type":"DRUG","name":"FTC/TDF","otherNames":["Truvada"]},{"type":"DRUG","name":"Stribild","otherNames":[]}],"arms":[{"label":"Stribild","type":"EXPERIMENTAL"},{"label":"NNRTI+FTC/TDF","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the noninferiority of Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF)) single-tablet regimen (STR) relative to regimens consisting of a nonnucleoside reverse transcriptase inhibitor (NNRTI) plus Truvada® (FTC/TDF) in maintaining HIV-1 RNA \\< 50 copies/mL at Week 48 in virologically suppressed, HIV-1 infected adults. This study will also evaluate the safety, tolerability, and efficacy of the two regimens through 96 weeks of treatment.","primaryOutcome":{"measure":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"Stribild","deltaMin":93.4,"sd":null},{"arm":"NNRTI+FTC/TDF","deltaMin":88.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.066"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":16,"exclusionCount":15},"locations":{"siteCount":80,"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Italy","Portugal","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["28689453","24908550"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":291},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Diarrhoea","Headache","Insomnia"]}}